- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05042609
A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma
A Phase 3 Randomized, Active-Controlled, Double-Masked Study to Evaluate the Safety and Efficacy of TRS01 Eye Drops in the Treatment of Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Lexitas Clinical Trials
- Phone Number: 919-205-0012
- Email: clinicaltrials@lexitas.com
Study Locations
-
-
-
Dijon, France, 21079
- Dijon
-
Lyon, France, 69004
- Lyon
-
Nantes, France, 44000
- Nantes
-
Paris, France, 75013
- Paris
-
Paris, France, 75014
- Paris
-
-
-
-
-
Bonn, Germany, 53127
- Bonn
-
Düsseldorf, Germany, 40225
- Düsseldorf
-
Freiburg, Germany, 79106
- Freiburg
-
Munster, Germany, 48145
- Munster
-
München, Germany, 80336
- München
-
Tübingen, Germany, 72076
- Tübingen
-
-
-
-
California
-
La Jolla, California, United States, 92093
- La Jolla
-
Los Angeles, California, United States, 90041
- Los Angeles
-
Los Angeles, California, United States, 90095-6984
- Los Angeles 2
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Aurora
-
Lakewood, Colorado, United States, 80228
- Lakewood
-
-
Florida
-
Jacksonville, Florida, United States, 32204
- Jacksonville
-
Winter Haven, Florida, United States, 33800
- Winter Haven
-
-
Georgia
-
Marietta, Georgia, United States, 30060
- Marietta
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Boston
-
Waltham, Massachusetts, United States, 02451
- Waltham
-
-
Missouri
-
Washington, Missouri, United States, 63090
- Washington, MO
-
-
New Jersey
-
Palisades Park, New Jersey, United States, 07650
- Palisades Park
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Winston-Salem
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Nashville
-
-
Texas
-
Austin, Texas, United States, 78712
- Austin
-
Plano, Texas, United States, 75075
- Plano
-
San Antonio, Texas, United States, 78240
- San Antonio
-
San Antonio, Texas, United States, 78238
- San Antonio 2
-
-
Virginia
-
Norfolk, Virginia, United States, 23502
- Norfolk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- At sites in the US: Male or female up to and including 75 years of age (including all pediatric age groups). At sites in the Europe: Male or female between 18 and 70 years of age, inclusive.
- Diagnosed with active non-infectious anterior uveitis with anterior chamber cell Grade 2 (6-15 cells) or Grade 3 (16-30 cells) in the study eye that are without any treatment or with Stable Medical Therapy requiring further treatment.
- Have Best Corrected Visual Acuity (BCVA) vision ≥ 65 letters in the non-study eye using Early Treatment Diabetic Retinopathy Study (ETDRS).
Exclusion Criteria:
- Pregnant or breastfeeding females or females.
- History of or active significant ocular disease in either eye.
- Uncontrolled intraocular pressure (IOP; defined as >27mmHg) or narrow angle glaucoma in either eye and/or are at risk of angle closure with dilating.
- Poor posterior view due to limitation of dilation or media opacity that limits ability to examine the posterior segment.
- Cancer or melanoma that is actively treated with immunotherapy.
- Certain clinically significant systemic diseases or conditions.
- Receiving specific medication/interventions as specified per protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TRS01
|
TRS01 eye drops Dosed four times a day (QID)
|
Active Comparator: Active comparator
|
FDA approved steroid eye drop Dosed four times a day (QID)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anterior Chamber Cell (ACC) grade on Day 28
Time Frame: 28 days
|
For FDA submission: the proportion of subjects with Anterior Chamber Cell (ACC) Grade=0 (0 cells) on Day 28 in the study eye. For submission to European Medicines Agency (EMA) related countries: the proportion of subjects with ACC Grade = 0 or 1 on Day 28 in the study eye. |
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline (Day 1) in ACC Grade on Day 28 in the study eye
Time Frame: 28 days
|
28 days
|
|
Anterior Chamber Cell (ACC) grade on Day 21
Time Frame: 21 days
|
For FDA submission: Proportion of subjects with ACC Grade=0 on Day 21 in the study eye. For submission to EMA related countries: Proportions of subjects with ACC Grade = 0 or 1 on Day 21 in the study eye. |
21 days
|
Change from baseline in ACC Grade on Day 21.
Time Frame: 21 days
|
21 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Lexitas Clinical Trials, Lexitas
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TRS4Vision
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Uveitic Glaucoma
-
Imperial College Healthcare NHS TrustIRIDEX CorporationNot yet recruitingGlaucoma | Glaucoma, Open-Angle | Glaucoma, Angle-Closure | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma Secondary | Glaucoma Traumatic | Glaucoma Uveitic
-
Guy's and St Thomas' NHS Foundation TrustCompleted
-
Wills EyeIOP OphthalmicsTerminatedPrimary Open Angle Glaucoma | Neovascular Glaucoma | Uveitic Glaucoma | Pseudoexfoliation Glaucoma | Primary Angle Closure Glaucoma | Pigmentary Glaucoma | Traumatic GlaucomaUnited States
-
Hoffmann-La RocheRecruitingUveitic Macular EdemaUnited States, Japan, Australia, Singapore, Turkey, Argentina, Czechia, Spain, France, Germany, Switzerland, India
-
Hoffmann-La RocheRecruitingUveitic Macular EdemaKorea, Republic of, United Kingdom, China, United States, Netherlands, Canada, Israel, Austria, Brazil, Italy, Taiwan, Poland, Portugal, Mexico
-
University of MiamiGenentech, Inc.CompletedUveitic Cystoid Macular EdemaUnited States
-
Centre hospitalier de l'Université de Montréal...CompletedGlaucoma | Glaucoma, Open-Angle | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma and Ocular Hypertension | Glaucoma, Uncompensated | Glaucoma SecondaryCanada
-
Pro Top & Mediking Company LimitedCompletedOpen Angle Glaucoma | Neovascular Glaucoma | Angle Closure Glaucoma | Uveitis Glaucoma | Young Age Glaucoma | High Risk PatientEstonia
-
Icahn School of Medicine at Mount SinaiWithdrawnUveitic Macular Edema | Intraocular InflammationUnited States
-
Sanoculis LtdCompletedPrimary Open Angle Glaucoma | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaIsrael
Clinical Trials on TRS01
-
Tarsier PharmaCompletedNon-infectious Anterior UveitisUnited States
-
Tarsier PharmaCompletedPost Surgical Ocular InflammationUnited States